Type 1 Diabetes Mellitus: A High-Yield USMLE Review
Type 1 diabetes mellitus is an autoimmune disease characterized by insulin deficiency, most commonly presenting in young patients and prone to diabetic ketoacidosis (DKA) when insulin is missed. Because it is an autoimmune condition, patients carry a higher risk of other autoimmune disorders. On the exam it appears most often as a young patient in DKA or as a patient with a coexisting autoimmune endocrinopathy.
Pathophysiology
Type 1 diabetes results from autoimmune destruction leading to insulin deficiency. Without insulin, the body cannot use glucose and shifts to fat breakdown, generating ketoacids that produce a high anion gap metabolic acidosis (DKA) with severe hyperglycemia. In DKA, acidosis drives potassium out of cells, so the measured serum potassium may be high even though total body potassium is depleted; giving insulin drives potassium back into cells and can precipitate dangerous hypokalemia. Because the underlying process is autoimmune, patients are predisposed to additional autoimmune endocrine failures such as thyroiditis and adrenalitis.
Presentation
- A young patient (e.g., 20s) who runs out of or misses insulin and develops DKA: nausea, abdominal pain, and hyperglycemia
- Signs of ketoacidosis with marked hyperglycemia (e.g., glucose ~420 mg/dL), high anion gap metabolic acidosis, and an initially elevated serum potassium
- Coexisting autoimmune disease — because Type 1 diabetes is autoimmune, patients are at higher risk for autoimmune thyroiditis and autoimmune (primary) adrenal insufficiency as part of a polyglandular syndrome
- Fatigue, nausea, weight loss, and orthostatic symptoms should raise concern for an associated autoimmune adrenal insufficiency in a known Type 1 diabetic
Diagnosis
- Metabolic labs demonstrating DKA: marked hyperglycemia, low pH and low bicarbonate, and an elevated anion gap with ketosis
- Serum potassium must be measured before initiating insulin — a high initial value reflects acidosis-driven extracellular shift despite total-body depletion
- In a Type 1 diabetic with hypotension, hyponatremia, and hyperkalemia, evaluate for coexisting primary adrenal insufficiency (Addison's) rather than assuming DKA
Management
- For DKA: start IV fluids, then check potassium before giving insulin. If K+ is low (<3.3), hold insulin and replace potassium first; if K+ is 3.3–5.3, give insulin and potassium together; if K+ is >5.3, give insulin and recheck potassium
- Ongoing management centers on insulin replacement; intensive glycemic control reduces the development and progression of long-term microvascular complications
High-yield
- The DKA potassium paradox: initial serum K+ may be high, but total body potassium is depleted — insulin shifts K+ into cells and can cause fatal arrhythmias if given before checking/replacing potassium
- In DKA, correct fluids first, then check potassium, then give insulin
- Type 1 diabetes is autoimmune and clusters with other autoimmune disorders — autoimmune thyroiditis (including postpartum thyroiditis) and primary adrenal insufficiency (polyglandular syndrome)
- Intensive treatment of insulin-dependent diabetes slows long-term complications (DCCT principle)
- Insulin-dependent diabetes is one of the six variables in the Revised Cardiac Risk Index (Lee criteria) for perioperative cardiac risk
Pitfalls
- Giving an immediate IV insulin bolus in DKA before checking potassium — insulin-driven hypokalemia can trigger fatal arrhythmias
- Mistaking the initially elevated serum potassium in DKA for a true potassium excess when total body stores are actually depleted
- Attributing new fatigue, weight loss, hypotension, hyponatremia, and hyperkalemia in a Type 1 diabetic solely to poor glycemic control while missing coexisting autoimmune primary adrenal insufficiency
Don't just memorize Type 1 Diabetes Mellitus — practice reasoning through it on branching cases where your decisions shape the patient.